Adze Biotechnology Inc
StreetZero Signal 76
About Adze Biotechnology Inc
Adze Biotechnology Inc is a clinical-stage oncolytic immunotherapy platform company with active programs in melanoma, breast cancer, and liver cancer. Its proprietary oncolytic backbone is designed for both systemic and intra-tumoral delivery, allowing variation of IO payloads. The company is headquartered in Coral Gables, Florida, and led by CEO Sidney Hopps.
LATEST FUNDINGPrivate Placement
$9.3M
Announced 2026-11-16
TOTAL RAISED$9.8M
IN THE NEWS
- ๐ Adze Biotechnology Inc - BIO Investment & Growth Summit 2027
- ๐ Adze Biotechnology 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- ๐ Adze Biotechnology - 2026 Company Profile, Funding & Competitors - Tracxn
- ๐ Adze Biotechnology Completes $6.2 Million First Closing of Series A Financing
- ๐ Adze Biotechnology | Oncolytic Immunotherapies for Cancer
EMPLOYEESโ
FOUNDED2018
HQCoral Gables, FL, United States
Industry
Biotechnology
Tags
BiotechnologyOncolytic ImmunotherapyClinical-StagePlatform
Investors
Key highlights
- Raised $6.2M first close of Series A in March 2023 to advance clinical programs.
- Platform enables both systemic and intra-tumoral delivery with customizable IO payloads.
- Actively seeking $30M Series B to fund multiple clinical programs with data readouts in late 2026.
- Holds Notice of Allowance for broad recombinant adenovirus IP claims.
- Competitors include Oncorus, Replimune, and Akamis Bio.
Ask StreetZero about Adze Biotechnology Inc
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account